Form 4: Arcus Biosciences Director, Patrick Machado, Reports Stock and Option Transactions

Director Patrick Machado reported the acquisition of restricted stock units and stock options in Arcus Biosciences on June 6, 2024.

Summary

• On June 6, 2024, Patrick Machado, a director of Arcus Biosciences, reported transactions involving the company's stock.
• Machado acquired 8,400 restricted stock units (RSUs) and 24,000 stock options.
• The RSUs vest fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will fully vest upon a change in control of the company.
• The stock options, with an exercise price of $15.90, also vest fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will fully vest and become exercisable upon a change in control.
• Machado also disposed of 25,300 common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects standard compensation practices. The acquisition of RSUs and options suggests confidence, but the disposal of common stock offsets this somewhat.

Positives

• The vesting of RSUs and stock options upon a change in control could be seen as a positive incentive for the director to act in the best interests of the company and its shareholders.

Future Outlook

The vesting of the RSUs and stock options is contingent upon continued service or a change in control, suggesting an ongoing commitment from the director.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's stock. This filing indicates the director's ongoing investment in the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting equity.

Key Dates